Mundipharma
Marc Princen has been the Global CEO at Mundipharma since May 2020. Prior to that, they served as the Executive Vice President and President of International Business at Allergan from December 2016 to May 2020. From November 2014 to December 2016, Princen was the President of Europe and Canada at Takeda. Marc was also a Corporate Officer and member of the Takeda Executive Team during that time. From October 2009 to October 2014, Princen served as the President of the Mid Europe Region at Merck. Marc was responsible for the Merck business in European markets ex the Europe 'Big Five'. Prior to that, Princen was the Regional Vice President Central, Eastern Europe and Middle East & Africa at Essex Pharma GmbH from October 2002 to June 2004. From July 2004 to June 2010, they served as the Regional Vice President at Schering Plough. And from January 2000 to September 2002, Princen was the Senior Director of Middle East Africa at Sentipharm (Schering Plough). Marc served as the General Manager at Schering Plough from October 1994 to December 1999.
Marc Princen studied at the Katholieke Universiteit (KU) in Leuven, Belgium, where they obtained a Bachelor of Science in Physiotherapy. Marc also attended St Jozefscollege in Hasselt.
Some direct reports include Francois Bernard - General Manager, France, Switzerland, Austria and CEE, Hywel Day - General Manager, Napp Pharmaceuticals, and Benoit Slavicek - Vice President Commercial Excellence.
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.